The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
LettersFull Access

A Case Report of Blonanserin-Induced Hyponatremia

To the Editor: A number of psychotropic drugs are known to cause hyponatremia. Blonanserin is an antipsychotic drug used mainly in Korea and Japan and has recently become available in India. It is reported to be well tolerated and has a safe side effect profile. Herein, I report a case of a middle-aged woman who had major depressive disorder with psychotic symptoms. After receiving blonanserin, she developed hyponatremia within a week of starting the drug. After discontinuation of the drug, the sodium level returned to normal. There have been no reported cases of blonanserin causing hyponatremia.

Case Report

A 54-year-old female patient who developed a single episode of major depressive disorder, with psychotic symptoms (DSM-IV-TR) of 3-month duration, was put on venlafaxine 150 mg/day and risperidone 4 mg/day. Over a period of 2 months, her depressive symptoms decreased considerably, and the psychotic symptoms subsided. Because she complained of sedation, which distressed the patient, risperidone was stopped, and blonanserin was started at a dose of 4 mg/day, which was increased to 8 mg/day after 1 week. She reported further improvement and no longer complained of sedation. Four days after the dose of blonanserin was changed to 8 mg/day, she developed light headedness, difficulty in concentration, tremulousness, fatigue, and severe generalized weakness; she needed support to walk. She was hospitalized and extensively evaluated for organic conditions. All her investigations were normal, but hyponatremia was detected (sodium level, 128 mmol/L). Blonanserin and venlafaxine were both discontinued. Her sodium levels returned to normal in 4 days. Her clinical condition improved, and the side effects disappeared within a week. She was discharged from the hospital after gradually reintroducing venlafaxine 150 mg/day, under close monitoring of sodium levels, which remained normal. One month later, she was in complete remission and had normal electrolyte levels. She is being regularly followed up.

Discussion

A number of psychotropic drugs are known to cause hyponatremia and syndrome of inappropriate secretion of antidiuretic hormone.1 Among antidepressants, selective serotonin reuptake inhibitors have been most reported to cause clinically significant hyponatremia. Although venlafaxine has potent serotonergic activity, it is much less likely to cause hyponatremia, and the reported cases of hyponatremia are generally clinically insignificant.2 Hyponatremia seen with venlafaxine usually manifests in a few days after onset.3 In this case, hyponatremia appeared more than 2 months after venlafaxine was started; reintroduction of venlafaxine did not cause hyponatremia. Therefore, it is reasonable to conclude that blonanserin caused the hyponatremia.

Dept. of Psychiatry, Rajarajeswari Medical College and Hospital, Bangalore 560074, India
Correspondence: Amar D. Bavle, M.D.; e-mail:
References

1 Al-Salman J, Kemp D, Randall D: Hyponatremia. West J Med 2002; 176:173–176Crossref, MedlineGoogle Scholar

2 Jung YE, Jun TY, Kim KS, et al.: Hyponatremia associated with selective serotonin reuptake inhibitors, mirtazapine, and venlafaxine in Korean patients with major depressive disorder. Int J Clin Pharmacol Ther 2011; 49:437–443Crossref, MedlineGoogle Scholar

3 Roxanas M, Hibbert E, Field M: Venlafaxine hyponatraemia: incidence, mechanism and management. Aust N Z J Psychiatry 2007; 41:411–418Crossref, MedlineGoogle Scholar